Mechanism of Action
FILSPARI targets two critical pathways involved in IgAN disease progression in one molecule1,3,4
FILSPARI is a DEARA, a dual endothelin angiotensin receptor antagonist, and the first and only single molecule, non-immunosuppressive therapy indicated for IgAN patients to reduce proteinuria1,3,4
FILSPARI targets two critical pathways, both the endothelin and angiotensin pathways, involved in IgAN disease progression 1,3,4
Endothelin 1, via ETAR, and angiotensin II, via AT1R, mediate processes that lead to IgAN progression through hemodynamic actions, mesangial cell proliferation, increased expression of pro-inflammatory and pro-fibrotic mediators, podocyte injury, and oxidative stress1
References & footnotes
Abbreviations
AT1R, angiotensin II type 1 receptor; DEARA, dual endothelin angiotensin receptor antagonist; ETAR, endothelin type A receptor; IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy; MoA, mechanism of action
References
- FILSPARI. EU SmPC. April 2024.
- Rovin B, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077–90.
- Campbell KN, et al. Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice. Int J Nephrol Renovasc Dis. 2023;16:281–91.
- Syed YY, et al. Sparsentan: First Approval. Drugs. 2023;83(6):563–8.
FILSPARI is contraindicated during pregnancy. FILSPARI treatment must only be initiated in women of childbearing potential when the absence of pregnancy has been verified. Women of childbearing potential have to use effective contraception during and up to 1 month after treatment has stopped.
This medicinal product has been granted a conditional marketing authorization by the European Commission.
▼ This medicinal product is subject to additional monitoring. This will allow identification of new safety information. This SmPC may be updated from time to time as necessary. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should also be reported to CSL Vifor at safety@viforpharma.com
Medicinal product subject to restricted medical prescription. Full prescribing information is available on request. Please read the full SmPC prior to administration. FILSPARI® is a registered trademark.
Vifor France. 100–101 Terrasse Boieldieu, Tour Franklin La Défense 8, 92042 Paris La Défense Cedex, France
Date of preparation: April 2024 | API job number: HQ-SPT-2400059
HQ-SPT-2500005 | Date of preparation: February 2025